Kadimastem (KDST.TA) Core Investment Case 11022025
Kadimastem (KDST.TA:TASE) is an Israeli-based clinical-stage cell therapy company pioneering regenerative medicine for insulin dependent type 1 diabetes (T1D) (no more injections) and amyotrophic lateral sclerosis (ALS). KDST has a proprietary stem-cell differentiation platform for scalable therapies designed to replace lost or damaged cells. KDST’s T1D IsletRx program aims to revolutionize insulin production for diabetes patients using off-the-shelf allogeneic encapsulated pancreatic islet cells with immune protection. AstroRx® targets neurodegenerative diseases (NDDs), particularly ALS. KDST.TA is merging with NLSP – a significant value inflection point.
ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.
We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.
Our independent research is designed to educate our professional investor readers with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.
We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.
Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.